Study of WVE-003 in Patients With Huntington's Disease

Status Recruiting

Clinical Trial Summary

This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of WVE-003 in adult patients with early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Huntington Disease

Clinical Trial Details

NCT number	NCT05032196
Study type	Interventional
Source	Wave Life Sciences Ltd.
Contact	Clinical Operations
Phone	855-215-4687
Email	clinicaltrials@wavelifesci.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	September 6, 2021
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03052712` - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies	N/A
Not yet recruiting	`NCT04429230` - Non-invasive Brain Stimulation in Huntington's Disease	N/A
Recruiting	`NCT03599076` - Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
Terminated	`NCT04617860` - Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease	Phase 1/Phase 2
Completed	`NCT05748288` - Development of the Virtual Unified Huntington's Disease Rating Scale
Not yet recruiting	`NCT04370470` - Development of Assessments for Later Stage HD
Recruiting	`NCT01834053` - Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.	Phase 1/Phase 2
Completed	`NCT01458470` - A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease	Phase 2
Completed	`NCT01357681` - Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)	Phase 2
Completed	`NCT00980694` - Bioavailability of Ubiquinol in Huntington Disease	Phase 1
Completed	`NCT00146211` - TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease	Phase 3
Recruiting	`NCT01412125` - Study of Biomarkers That Predict the Evolution of Huntington's Disease	N/A
Completed	`NCT00075140` - Family Health After Predictive Huntington Disease (HD) Testing	Phase 3
Recruiting	`NCT04818060` - Preparing for Prevention of Huntington's Disease (PREVENT-HD)
Active, not recruiting	`NCT04698551` - NIPD on cffDNA for Triplet Repeat Diseases
Not yet recruiting	`NCT04301726` - Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD	Phase 1
Completed	`NCT03421327` - Genetic Risk: Whether, When, and How to Tell Adolescents
Recruiting	`NCT03296176` - Metabolomic Study in Huntington's Disease (METABO-HD)	N/A
Recruiting	`NCT05243017` - Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease	Phase 1/Phase 2
Recruiting	`NCT06082713` - Extracellular Vesicles for HD